Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.
We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
Perspectum announced today it has been given US FDA clearance to market its test for diagnosing and measuring liver disease.
Outside London, it is arguable that no other region has had more of an effect on the evolution of the UK than Oxford. From custodians of the English language to leaders of the country, Oxford has continued to have a major impact on the shape and destiny of the British people.
Isis Innovation spinout NightstaRx Ltd (“Nightstar”), a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, has announced a $35 million Series B financing round.
A £50m fund for investing in UK technology for application in China has been launched as part of Chinese President Xi Jinping’s official trip to the UK. Isis Innovation is acting as consultant to the fund.
Isis Outcomes will be represented at the ISPOR 18th Annual European Congress to be held in Milan, from November 7th-11th 2015.